within Pharmacolibrary.Drugs.ATC.S;

model S01BC04
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 1.35e-06,
    adminDuration  = 600,
    adminMass      = 50 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00014000000000000001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0001,
    k12             = 0.073,
    k21             = 0.073
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>S01BC04</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Flurbiprofen is a non-steroidal anti-inflammatory drug (NSAID) used primarily for its analgesic, anti-inflammatory, and antipyretic properties. It is typically indicated for the treatment of pain, such as sore throat, musculoskeletal pain, and ocular inflammation. As an eye drop (S01BC04), it is approved and used for prevention and treatment of postoperative miosis and inflammation after cataract surgery.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters for flurbiprofen reported in healthy adult subjects after intravenous administration.</p><h4>References</h4><ol><li><p>He, Y, et al., &amp; Qin, F (2023). Comparison of in vivo pharmacokinetic behaviors of R- and S-flurbiprofen after intravenous injection of flurbiprofen axetil. <i>Chirality</i> 35(4) 247–255. DOI:<a href=&quot;https://doi.org/10.1002/chir.23531&quot;>10.1002/chir.23531</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36759185/&quot;>https://pubmed.ncbi.nlm.nih.gov/36759185</a></p></li><li><p>Kumpulainen, E, et al., &amp; Kokki, H (2010). Plasma and cerebrospinal fluid pharmacokinetics of flurbiprofen in children. <i>British journal of clinical pharmacology</i> 70(4) 557–566. DOI:<a href=&quot;https://doi.org/10.1111/j.1365-2125.2010.03720.x&quot;>10.1111/j.1365-2125.2010.03720.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/20840447/&quot;>https://pubmed.ncbi.nlm.nih.gov/20840447</a></p></li><li><p>Verma, P, et al., &amp; Trevaskis, NL (2016). Single Intravenous Dose of Novel Flurbiprofen-Loaded Proniosome Formulations Provides Prolonged Systemic Exposure and Anti-inflammatory Effect. <i>Molecular pharmaceutics</i> 13(11) 3688–3699. DOI:<a href=&quot;https://doi.org/10.1021/acs.molpharmaceut.6b00504&quot;>10.1021/acs.molpharmaceut.6b00504</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27632682/&quot;>https://pubmed.ncbi.nlm.nih.gov/27632682</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end S01BC04;
